← All trials
NCT06582277
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2024
- Primary completion
- Mar 31, 2025
- Completion date
- Aug 31, 2025
- First posted
- Sep 3, 2024
- Last posted
- Sep 3, 2024
- Enrollment
- 214
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Osivax S.A.SLead sponsor
- Osivax S.A.SOfficial
- Harmony Clinical ResearchCollaborator
- KCAS BioCollaborator
- Ghent UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.